Pharmafile Logo

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

- PMLiVE
The US government passed the Orphan Drug Act in 1983, and it was subsequently adopted in other key markets, most notably in Japan in 1993 and the European Union in 2000. Growth in this sector has remained around 12% annually, which is more than double that experienced in the general drug market. According to the 2015 Orphan Drug Report, worldwide orphan drug sales will reach $178 billion by 2020 and will account for 20% of all prescription drug sales by 2020*. 

The trend is clear: as science and technology advances, and the rise of the internet and social media enables patients and researchers to gather and share information more effectively, we are seeing treatments for rare diseases that only a few years ago would have led to an early death. 

Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise in their medical education agencies is paramount. Lucid recognised this and structured its business last year to create a unit specialising in rare diseases.” 

Within this unit, Lucid Group had recruited a team of highly skilled medical writers who combine a deep and robust understanding of the science with experience of working with rare disease specialists across the globe.

“Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. It is essential to build networks and enable best practice sharing,” Alison explains. “And in rare disease, more so than in any other therapy area, the choice of agency is crucial, as often it is your agency who represents your organisation at the communication level – so its voice has to be your voice.” 

Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. So raising awareness, improving time to diagnosis, getting patients to the right care, and improving family and emotional support and reimbursement are just some of the areas where medical education agencies can support pharma clients. 

Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU.  For further information about working with Lucid’s Rare Disease Business Unit, please call Alison on 01494 552078 or email alison@lucid-uk.com. 

* EvaluatePharma Orphan Drug Report 2015

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid Group’s winning talent team

The Lucid Group talent team has grown with two new Talent Acquisition Partners: Jon Turner and Ellen Field. To help you understand a bit more about them, their role, and the opportunities...

Solving healthcare problems: What needs to change?

In this month’s PME, Tanya Goodyear, Director of Innovation and Transformation at Lucid Group, details Lucid’s approach to solving healthcare problems and reflects on the learnings we can draw from...

Lucid Group celebrates a double win at Communiqué 2021

Lucid scooped a double win at this year’s Communiqué awards, the first face-to-face industry event since the start of the pandemic – making it an extra-special occasion for everyone attending....

Another Landmark Lucid Workiversary

We’re celebrating another landmark Workiversary with Richard Barry, Senior Medical Writer. Richard has now been a Lucidian for an impressive 10 years, so we thought it was only fitting to...

Summer Fridays are back at Lucid Group

Summer Fridays are back, bringing some much deserved R&R for our people.☀️A ‘Summer Friday’ means that employees are now actively encouraged to finish work from 2 pm on alternate Fridays...

The Spirit of Lucid Group

Since 2017, Lucid Group’s charity working group, LUCID SPIRIT, has been actively involved in helping to raise awareness and funds for its charity partners. At launch, Lucid Spirit partnered with the...

Staying in the loop – six principles for impactful integrated communications

In a digitalised world, accelerated by the COVID-19 pandemic, pharmaceutical companies must work smarter to engage busy external stakeholders with endless content at their fingertipsIn this month’s edition of PME James...

Lucid Group acquires US-based strategic brand consultants DiD

Lucid Group has acquired the US-based strategic brand consultants, DiD. This union will strengthen Lucid Group’s existing presence in the US and its ability to provide a compelling strategic, creative...

Day in a #LucidLife – Meet Jack

Take a look at what it's like working at Lucid Group. Jack discusses his experience of Lucid's Futures Academy, of transitioning to a fully remote workforce in lockdown, Lucid's culture...

Lucid Group make the cut for Communiqué in seven different categories.

Lucid Group’s pioneering approach to healthcare communications has been recognised with five of its programmes making the shortlist across five categories, as well as making the finals for the two company awards:The five shortlisted programme category awards are:EXCELLENCE IN NATIONAL OR LOCAL EDUCATION MEETINGS/STAND-ALONE...